The Patent Finder

Terms ending in 2043

CureVac AG

Every in-force patent on CureVac AG's record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 12,589,078Lipid Nanoparticles for Delivery of Nucleic Acids
In force
 · High confidence
Curevac SEIn forceHigh confidence
US 12,186,389NUCLEIC ACID BASE VACCINE AGAINST EMERGING SARS-CoV-2 VARIANTS
In force
 · High confidence
GlaxoSmithKline Biologicals S.A.In forceHigh confidence
2 of 2 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by CureVac AG.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited